Sumitomo Dainippon Pharma Co., Ltd. Announces Organizational Realignment, Effective from April 1, 2016; Announces Executive Changes
March 01, 2016 at 06:30 am EST
Share
Sumitomo Dainippon Pharma Co. Ltd. announced organizational realignment, effective from April 1, 2016. The Corporate Governance is created, Corporate Communications is dissolved as a department, General Affairs is dissolved as a department, Global R&D Office is dissolved and its functions are transferred to Global Corporate Planning, Career Development is dissolved and its functions are transferred to Personnel, Procurement is dissolved and its functions are transferred to Corporate Service Center and Manufacturing Management. Sub-divisions Higashi-Nippon Region and Nishi-Nippon Region are both dissolved and all the Region Management (Departments) under these sub-divisions are dissolved, tokyo Branch is created by integrating Tokyo Branch I and Tokyo Branch II, Tokai Branch is created by integrating Shizuoka Branch and Nagoya Branch, Keiji-Hokuriku Branch is created by integrating Hokuriku Branch and Keiji Branch, Osaka Branch is created by integrating Osaka Branch I and Osaka Branch II, and Kyushu Branch is created by integrating Kyushu-kita Branch and Kyushu-minami Branch.
The company announced Promotion of Hiroshi Nomura (currently Member, Board of Directors, Senior Executive Officer) as Member, Board of Directors, Executive Vice President, effective from April 1, 2016. Yoshiharu Ikeda (currently Executive Officer), Hitoshi Odagiri (currently Executive Officer), Kazuo Koshiya (currently Executive Officer) promoted as Senior Executive Officer, effective from April 1, 2016. The company appointed Hideyuki Harada (currently Director, Research Planning & Intelligence) as Executive Officer, effective from April 1, 2016. The company also announced retiring of Makoto Hara (currently Member, Board of Directors, and Executive Vice President), Yoshihiro Okada (currently Member, Board of Directors, Senior Executive Officer), and Susumu Nakajima (currently Senior Executive Officer) as Executive Officers, effective from March 31, 2016.
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).